CLL Evolution: Fixed-Duration Therapy, NCCN Guidelines, and Managed Care

In this episode of Unscripted, the AMCP podcast, host Laura Bobolts, PharmD, BCOP, talks with Kirollos Hanna, PharmD, Director of Pharmacy at Minnesota Oncology, about the rapidly shifting treatment landscape for chronic lymphocytic leukemia (CLL). The discussion covers the transition toward oral fixed-duration frontline regimens, the latest 2026 NCCN guidelines, and the emerging role of MRD testing. They also explore the clinical and economic implications of these therapies, including how the Inflation Reduction Act (IRA) is reshaping Medicare formulary strategies and patient access.

View AMCP's Inflation Reduction Act (IRA) University Course

This podcast is sponsored by Abbvie

Unscripted offers valuable updates for listeners and connects sponsors with health care professionals, payers, policymakers, regulators, and industry leaders. Sponsors benefit from a platform that connects them with a wide network of health care professionals, payers, and industry leaders. View podcast partner and advertising options, and view other Corporate Opportunities.

See main page: AMCP.org/podcast